Crossject and the US Department of Defense - DOD - (who is in charge of chemical, biological, radiological and nuclear defense – JPM CBRN Medical) have signed a cooperative research and development agreement for Zeneo® Midazolam.
« We are really happy to have signed this cooperative research and development agreement with the US Department of Defense (DOD), after their audit when they came to visit us in Dijon last July. We share a common interest by helping protecting the forces’ troops against nerve agents’ attacks. The Food and Drug Administration and the DOD are really working together to help with development and use of specific pharmaceutical products.
Patrick Alexandre, CEO of Crossject